English
VEGF Blocker
VEGF Blocker
Artikelnummer
BPS102019-1
Verpackungseinheit
25 µg
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: Useful for studying the neutralization of VEGFR in ELISA and in cellular assays.
Assay Conditions: Assay was done according to VEGFR1: VEGF165 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (#82632) with various amounts of VEGF Blocker.
Background: VEGF165 (Vascular Endothelial Growth Factor 165), a potent isoform of VEGF-A, belongs to the VEGF family of homodimer glycoproteins and is produced and secreted by various cells when angiogenesis is required. Angiogenesis involves endothelial cell proliferation, migration, and formation of blood vessels, which under normal conditions serve to provide nutrients and oxygen to tissues during development or wound healing. However, tumor cells can promote new blood vessel formation by secreting pro-angiogenesis factors. VEGF-A can bind to both VEGFR1 (Vascular Endothelial Growth Factor Receptor 1) and VEGFR2, also known as KDR (kinase insert domain receptor), on the surface of endothelial cells or cancer cells. VEGFR2 is considered the main signaling receptor, while VEGFR1 leads to a weak signaling and can be seen as a decoy receptor. Ligand binding induces VEGFR2 receptor dimerization and activates its tyrosine kinase activity. As a result, multiple downstream signaling cascades, including the MAPK (mitogen activated protein kinase) pathway, get activated. The VEGF-VEGFR signal pathway has been a significant target in therapeutic strategies aimed at controlling angiogenesis in diseases like cancer and AMD (age macular degeneration), and several small molecules, neutralizing antibodies and blockers have been FDA-approved. However, the development of drug resistance is still a challenge. The use of combinatory therapy or development of new generation drugs will continue to benefit cancer therapy.
Description: VEGF Blocker is a fusion protein composed of the extracellular domain that binds to VEGF (vascular endothelial growth factor) of VEGFR1 (vascular endothelial growth factor receptor 1), the extracellular domain that binds to VEGF of VEGFR2 and the Fc domain of human IgG1. This protein was affinity purified. VEGF Blocker is similar to Aflibercept.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
Application: Useful for studying the neutralization of VEGFR in ELISA and in cellular assays.
Assay Conditions: Assay was done according to VEGFR1: VEGF165 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit (#82632) with various amounts of VEGF Blocker.
Background: VEGF165 (Vascular Endothelial Growth Factor 165), a potent isoform of VEGF-A, belongs to the VEGF family of homodimer glycoproteins and is produced and secreted by various cells when angiogenesis is required. Angiogenesis involves endothelial cell proliferation, migration, and formation of blood vessels, which under normal conditions serve to provide nutrients and oxygen to tissues during development or wound healing. However, tumor cells can promote new blood vessel formation by secreting pro-angiogenesis factors. VEGF-A can bind to both VEGFR1 (Vascular Endothelial Growth Factor Receptor 1) and VEGFR2, also known as KDR (kinase insert domain receptor), on the surface of endothelial cells or cancer cells. VEGFR2 is considered the main signaling receptor, while VEGFR1 leads to a weak signaling and can be seen as a decoy receptor. Ligand binding induces VEGFR2 receptor dimerization and activates its tyrosine kinase activity. As a result, multiple downstream signaling cascades, including the MAPK (mitogen activated protein kinase) pathway, get activated. The VEGF-VEGFR signal pathway has been a significant target in therapeutic strategies aimed at controlling angiogenesis in diseases like cancer and AMD (age macular degeneration), and several small molecules, neutralizing antibodies and blockers have been FDA-approved. However, the development of drug resistance is still a challenge. The use of combinatory therapy or development of new generation drugs will continue to benefit cancer therapy.
Description: VEGF Blocker is a fusion protein composed of the extracellular domain that binds to VEGF (vascular endothelial growth factor) of VEGFR1 (vascular endothelial growth factor receptor 1), the extracellular domain that binds to VEGF of VEGFR2 and the Fc domain of human IgG1. This protein was affinity purified. VEGF Blocker is similar to Aflibercept.
Format: Aqueous buffer solution.
Formulation: 8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
Purity: ≥90%
Storage Stability: At least 12 months at -80°C.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
| Artikelnummer | BPS102019-1 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 102019-1 |
| Verpackungseinheit | 25 µg |
| Mengeneinheit | STK |
| Methode | ELISA |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
